Nausea Clinical Trial
— NAVIGATEOfficial title:
A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.
Status | Not yet recruiting |
Enrollment | 148 |
Est. completion date | December 2027 |
Est. primary completion date | January 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Willing and able to complete the informed consent process - Stated willingness to comply with all study procedures and availability for the duration of the study - Aged =18 years at time of informed consent - Chronic, drug-refractory nausea that: a) has been present for more than 6 months, and b) has been active within the last 3 months prior to consent - Patient is able to complete ANMS GCSI-DD surveys on a compatible smart device with: a) a minimum of four (4) ANMS GCSI-DD entries per week for two consecutive weeks, and b) an average ANMS GCSI-DD score for nausea severity of =2.5 during the same two-week period - Refractory or intolerant to two or more of the following antiemetic drug classes: antihistamines, phenothiazines, serotonin type 3 receptor antagonists, dopamine type 2 receptor antagonists, anticholinergics, neurokinin receptor antagonists - Medically stable, in the opinion of the investigator, during the month prior to consent, with no planned modifications to medical therapy during the course of the study - Normal gastric emptying as assessed by a qualifying gastric emptying test performed within 6 months prior to consent - Normal upper endoscopy within 1 year prior to consent (e.g., absence of obstructions, ulcers, or cancers in the esophagus, stomach, or duodenum) Exclusion Criteria: - Cognitive impairment or other characteristic that would limit a patient's ability to complete study requirements - Evidence of a delayed gastric emptying test result within 2 years of consent - Documented gastrointestinal (GI) obstruction or pseudo-obstruction - History of primary swallowing disorders - History of primary psychogenic vomiting - History of primary eating disorder - History of cyclic vomiting syndrome - History of rumination syndrome - History of scleroderma - History of amyloidosis - History of cannabis hyperemesis syndrome - Active H. pylori infection - Evidence of bezoar during most recent endoscopy - Previous gastric surgery of any type - Uncontrolled thyroid disorder, in the opinion of the investigator - History of seizures disorders - Hemoglobin A1c >8.0% - Peritoneal dialysis or unstable hemodialysis - Parenteral or enteral nutritional support - History of organ transplant, chronic pancreatitis, gross malabsorptive syndromes, celiac disease, or inflammatory bowel disease - Other GI tract diseases and disorders that the investigator believes may have caused the patient's drug-refractory nausea and/or vomiting - Malignancy (with the exception of basal cell carcinoma of the skin) currently present, initially diagnosed or recurring within 5 years of consent - Opioid use - Current cannabis/cannabinoid use that exceeds: 3 days of usage per week, or 2 occurrences during each day of use, or 3 grams of total usage per week - Heavy alcohol use, defined as: for men, consuming five or more drinks on any day or 15 or more per week; for women, consuming four or more drinks on any day or 8 or more per week - Injection of Botox into the pyloric sphincter within 6 months of consent - Active major levels of anxiety/depression, as determined by the investigator - History of other clinically significant disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the patient or impact the validity of the study results - Life expectancy <1 year - Pregnant or breastfeeding at the time of consent or intend to become pregnant during the study - Any underlying disease leading to follow-up by MRI outside of current MR conditional indications - Glucagon-like peptide 1 (GLP-1) agonist drug use in 12 months prior to consent - Participation in other investigational clinical studies - Existing or prior gastric electrical stimulator implantation |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Enterra Medical, Inc. | Bright Research Partners |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Nausea Severity Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) nausea severity score | 4 Months | |
Secondary | Change in Vomiting Absolute Frequency | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) weekly vomiting absolute frequency. Analysis only performed if =64 evaluable participants have a baseline weekly vomiting frequency of =5 per week | 4 Months | |
Secondary | Change in Nausea Severity Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) nausea severity score | 12 Months | |
Secondary | Change in Vomiting Absolute Frequency | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) weekly vomiting absolute frequency. Analysis only performed if =64 evaluable participants have a baseline weekly vomiting frequency of =5 per week | 12 Months | |
Secondary | Change in Total Symptom Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) total symptom score | 4 Months | |
Secondary | Change in Total Symptom Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) total symptom score | 12 Months | |
Secondary | Change in Quality of Life Score | As measured by the Patient Assessment of Upper Gastrointestinal Disorders Quality of Life (PAGI-QoL) score | 12 Months | |
Secondary | Change in Quality of Life Score | As measured by the Patient Assessment of Upper Gastrointestinal Disorders Quality of Life (PAGI-QoL) score | 4 Months | |
Secondary | Change in Early Satiety Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) early satiety score | 4 Months | |
Secondary | Change in Postprandial Fullness Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) postprandial fullness score | 4 Months | |
Secondary | Change in Abdominal Pain Score | As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) abdominal pain score | 4 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
Completed |
NCT02939287 -
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
|
Phase 3 | |
Not yet recruiting |
NCT06055192 -
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
|
||
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT02462811 -
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
|
Phase 3 | |
Completed |
NCT01007500 -
Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery
|
Phase 4 | |
Recruiting |
NCT00528554 -
Laser Acupuncture Against Nausea in Children
|
N/A | |
Completed |
NCT00537875 -
Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens
|
N/A | |
Completed |
NCT00394966 -
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00946387 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT00947128 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT05433636 -
Mindful Waiting Room
|
N/A | |
Not yet recruiting |
NCT04827108 -
Psychometric Properties of the Chinese Version of PeNAT
|
||
Not yet recruiting |
NCT04853303 -
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Recruiting |
NCT04181346 -
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
Recruiting |
NCT03679182 -
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
|
Phase 2 | |
Completed |
NCT02618343 -
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
|
N/A | |
Terminated |
NCT01405924 -
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
|
Phase 2 | |
Recruiting |
NCT04116697 -
A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan
|
N/A |